Feasibility and Safety of Single-Probe Cryoablation with Liquid Nitrogen: An Initial Experience in 24 Various Tumor Lesions

Kammoun, Tarek; Prévot, Elodie; Serrand, Chris; Perolat, Romain; Forges, Hélène de; Houédé, Nadine; Beregi, Jean‐Paul; Frandon, Julien

doi:10.3390/cancers14215432

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detected hematomas in our study were solely identified on CT, and none presented clinical relevance or necessitated transfusion. In a prior study involving 22 patients treated across various organs using the same device, no significant complications were reported, particularly concerning bleeding [14]. Some operators, due to anticipated risks, opted to embolize the puncture path utilizing resorbable gelatin or glue.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors

Moulin,

Kammoun,

Audoual

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Kidney cancer accounts for 3% of adult malignancies and is increasingly detected through advanced imaging techniques, highlighting the need for effective treatment strategies. This retrospective study assessed the safety and efficacy of a new single-probe percutaneous cryoablation system using liquid nitrogen for treating T1a renal cancers. From May 2019 to May 2022, 25 consecutive patients from two academic hospitals, with a median age of 64.8 years [IQR 59; 75.5], underwent cryoablation for 26 T1a renal tumors. These tumors had a median size of 25.3 mm [20; 30.7] and a median RENAL nephrometry score, indicating tumor complexity, of 7 [5; 9]. No major complications arose, but three non-clinically relevant perirenal hematomas were detected on post-procedure CT scans. With a median follow-up of 795 days [573; 1020], the primary local control rate at one month stood was 80.8% (21 out of 26). The five recurrent lesions, which exhibited a higher renal score (p = 0.016), were treated again using cryoablation, achieving a secondary local control rate of 100%. No patient died, and the disease-free survival rate was 92% (23 out of 25). In conclusion, single-probe percutaneous cryoablation emerges as a promising modality for managing small renal masses. Notably, recurrence rates appear influenced by RENAL nephrometry scores, suggesting a need for further research to refine the technique.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The safety and effectiveness of this equipment have been documented in a randomized clinical trial focused on the treatment of low-grade breast cancers [13]. This innovation paves the way for potential treatments across a wider range of organs [14,15].…”

Section: Introductionmentioning

confidence: 99%

Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors

Moulin,

Kammoun,

Audoual

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

Liquid nitrogen-based cryoablation: complication rates for lung, bone, and soft tissue tumors cryoablation

Orsi,

Hamiddin,

Sattin

et al. 2024

British Journal of Radiology

View full text Add to dashboard Cite

Objective This study aimed to assess the complication rate during and 24 hours after cryoablation in lung, bone, and soft tissue tumors. Methods We reviewed complications in a total of 85 consecutive patients who underwent cryoablation using a liquid nitrogen-based system in various lesions between April 2017 and October 2022. There were no liver and renal lesions. Complications were categorized using the Society of Interventional Radiology classification. Results Eighty-five patients were treated for 96 lesions in the bone (36.4%; 35 of 96), lung (18.8%; 18 of 96), and soft tissue (44.8%; 43 of 96). The primary technical success rate was 97.7% (83 of 85). The total grade 2 and 1 complication rates were 5.2% (5/96) and 20.8% (20/96), respectively. Two patients had asymptomatic pulmonary embolisms incidentally noted at the 24-hour follow-up computed tomography (grade 2). The most frequent complications were simple and hemorrhagic pleural effusions (18.7%; 18 of 96). Lung procedures had the highest complication rate, where 13 patients (72.2%; 13 of 18) reported complications, including 2 cases of symptomatic hydropneumothorax requiring drainage (grade 2) and an additional 2 days of hospital stay. Eight patients (24.2%; 8 of 33) with bone lesions and 4 (9.3%; 4 of 43) with soft tissue lesions experienced complications. Conclusion Cryoablation using a liquid nitrogen-based system is safe, with only minor complications observed. Advances in knowledge This study provides data on the safety of liquid nitrogen-based percutaneous cryoablation in tumors located in lung, in bones and in soft tissues. Despite using larger diameter cryoprobes than those typically reported with argon-based system, our experience shows that complications are mostly low and comparable in frequency and severity.

show abstract

The use of ablation technologies for the treatment of hepatic metastases of colorectal cancer

Kostyleva,

Yusupov

2024

UJCS

View full text Add to dashboard Cite

show abstract

Feasibility and Safety of Single-Probe Cryoablation with Liquid Nitrogen: An Initial Experience in 24 Various Tumor Lesions

Cited by 4 publications

References 32 publications

Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors

Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors

Liquid nitrogen-based cryoablation: complication rates for lung, bone, and soft tissue tumors cryoablation

The use of ablation technologies for the treatment of hepatic metastases of colorectal cancer

Contact Info

Product

Resources

About